Press Releases

Date Title and Summary Additional Formats
Toggle Summary Innoviva to Report Third Quarter Financial Results on October 25 at 5:00 p.m. EDT
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the third quarter ended September 30, 2017 after market close on Wednesday, October 25, 2017 . Following the earnings release, Innoviva management will host a webcast and
View HTML
Toggle Summary Innoviva to Participate in Cantor Fitzgerald's Global Healthcare Conference on September 26
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer and Eric d'Esparbes, SVP and Chief Financial Officer will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September
View HTML
Toggle Summary GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations
Trelegy Ellipta met study primary endpoint demonstrating reduction in exacerbations compared with the dual therapies Anoro Ellipta and Relvar/Breo Ellipta in patients with COPD LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc.
View HTML
Toggle Summary Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US
LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under the brand name
View HTML
Toggle Summary Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion from the CHMP in Europe for Appropriate Patients with COPD
LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for fluticasone
View HTML
Toggle Summary Positive Results from Pioneering Salford Lung Study in Asthma Published in The Lancet, and Presented at European Respiratory Congress
Relvar Ellipta was superior to usual care treatment in improving asthma control for patients in Salford Lung Study. LONDON & BRISBANE, Calif. --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive results from the Salford Lung Study
View HTML
Toggle Summary Innoviva to Participate in Morgan Stanley's Global Healthcare Unplugged Conference on September 12
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present in a fireside chat format discussion at the Morgan Stanley 15th Annual Global Healthcare Conference at the Grand Hyatt Hotel in
View HTML
Toggle Summary Innoviva to Participate in Baird Global Healthcare Conference on September 7
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer and Eric d'Esparbes, the Company's Senior Vice President and Chief Financial Officer will participate in the 2017 Baird Global Healthcare
View HTML
Toggle Summary Innoviva Completes Refinancing of its 9% 2029 Non-Recourse Notes
Closes $250 Million Term B Loan Refinancing plan expected to reduce the associated current cash interest expense by nearly one-half BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (" Innoviva" or the "Company") (NASDAQ: INVA) today announced the closing of a $250 million Term B Loan (the "Term
View HTML
Toggle Summary Innoviva, Inc. Announces Closing of $175 Million Offering of 2.50% Convertible Senior Notes and Exercise of the Initial Purchasers' $17.5 million Over-Allotment Option
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced that it closed its offering of the Company's 2.50% convertible senior notes due 2025 (the "Notes") for gross proceeds of $192.5 million in aggregate principal.
View HTML

Copyright West LLC. Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.